Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Pharmacodynamics of ISIS 301012 in Hypercholesterolemic Subjects on Stable Statin Therapy

NCT00231569 is registered in ClinicalTrials.gov with Kastle Therapeutics, LLC as lead sponsor.

NCT NCT00231569
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00231569 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety and Pharmacodynamics of ISIS 301012 in Hypercholesterolemic Subjects on Stable Statin Therapy
Lead sponsor
Kastle Therapeutics, LLC
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2005
Completion date
December 31, 2007
Enrollment
74 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hypercholesterolemia